{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T13:19:37Z","timestamp":1792847977271,"version":"4.5.0"},"reference-count":32,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"25","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2007,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We investigated the risk factors and management of pleural effusion associated with dasatinib therapy for chronic myelogenous leukemia (CML) after failure of imatinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>We analyzed 138 patients with CML treated with dasatinib from November 2003 to January 2006 in one phase I (n = 50) and four phase II (n = 88) studies for the development of pleural effusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Pleural effusion occurred in 48 patients (35%; grade 3\/4 in 23 [17%]), including 29% of those treated in chronic phase (CP), 50% in accelerated phase (AP), and 33% in blast phase (BP). By multivariate analysis, history of cardiac disease, hypertension, and use of a twice-daily schedule (v once daily) were identified as factors associated with development of pleural effusions. Effusions were exudative in 78% of the assessable cases. In some patients, effusions were associated with reversible increments of right ventricular systolic pressure. Management included transient dasatinib interruption in 83%, diuretics in 71%, pulse steroids in 27%, and thoracentesis in 19% of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pleural effusions occur during dasatinib therapy, particularly among patients in AP or BP. A twice-daily schedule may result in a higher incidence of pleural effusion. Close monitoring and timely intervention may allow patients to continue therapy and achieve the desired clinical benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2007.12.0329","type":"journal-article","created":{"date-parts":[[2007,8,30]],"date-time":"2007-08-30T18:23:26Z","timestamp":1188498206000},"page":"3908-3914","source":"Crossref","is-referenced-by-count":317,"title":["Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure"],"prefix":"10.1200","volume":"25","author":[{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"first","affiliation":[{"name":"From the Department of Leukemia and Department of Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia and Department of Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia and Department of Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautham","family":"Borthakur","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia and Department of Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bruzzi","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia and Department of Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginald","family":"Munden","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia and Department of Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia and Department of Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00096-X"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062538"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3097"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1021\/jm049486a"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Cortes J, Rousselot P, Kim DW, et al: Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109:3207,2006-3213,","DOI":"10.1182\/blood-2006-09-046888"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047266"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046839"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0181"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-77-4-507"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020233"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1378\/chest.116.1.212"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3530"},{"key":"R16","unstructured":"Lee F, Lombardo, L, Camuso, A, et al: BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad spectrum anti-tumor activities in vitro and in vivo. Proc Am Assoc Cancer Res 46:159,2005,  (abstr 675)"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200317929"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Hellstrom M, Kalen M, Lindahl P, et al: Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126:3047,1999-3055,","DOI":"10.1242\/dev.126.14.3047"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5323.242"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.032"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200211000-00020"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Park YH, Park HJ, Kim BS, et al: BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett 243:16,2005-22,","DOI":"10.1016\/j.canlet.2005.11.014"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00347.x"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(03)00544-X"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-2725(02)00069-9"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(00)80213-0"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cellbio.13.1.513"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1006\/excr.1999.4732"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Cortes J, Kantarjian, H, Baccarani, M, et al: A phase 1\/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib. Blood 108,2006,  (abstr 168)","DOI":"10.1182\/blood.V108.11.168.168"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1199"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Kim, DW, Rousselot, P, et al: Dasatinib (SPRYCEL) 50mg or 70mg BID versus 100mg or 140mg QD in patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant or intolerant to imatinib: Results of the CA180-034 study. Blood 108,2006,  (abstr 166)","DOI":"10.1182\/blood.V108.11.166.166"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Ottmann, O, Pasquini, R, et al: Dasatinib (SPRYCEL) 140 mg once daily (QD) vs 70 mg twice daily (BID) in patients (pts) with advanced phase chronic myeloid leukemia (ABP-CML) or Ph+ ALL who are resistant or intolerant to imatinib (im): results of the CA180-035 study. Blood 108,2006,  (abstr 746)","DOI":"10.1182\/blood.V108.11.746.746"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2007.12.0329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T16:12:20Z","timestamp":1653495140000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2007.12.0329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,1]]},"references-count":32,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2007,9,1]]}},"alternative-id":["10.1200\/JCO.2007.12.0329"],"URL":"https:\/\/doi.org\/10.1200\/jco.2007.12.0329","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,1]]}}}